Home › Immunoblastic Lymphadenopathy › New York
Pag-aaral pangklinika para sa Immunoblastic Lymphadenopathy sa New York
5 pag-aaral para sa Immunoblastic Lymphadenopathy ang naghahanap ng mga kalahok sa mga site sa New York.
Mga Lungsod sa New York
Opisyal na teksto ng pag-aaral (English)
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medicine, New York
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06561048A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, New York
- Clinical Trial Site, New York
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT06393738Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- at 5 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT04803201A Registry for People With T-cell Lymphoma
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Weill Cornell Medical Center (Data Collection Only), New York
- at 2 pa
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 20, 2026 · NCT05978141Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Columbia University, New York
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2025 · NCT04234048Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.